Evidence map›Paper›PMID 28389745›Full record

Trial reportPediatric nephrology (Berlin, Germany)2017

Short, frequent, 5-days-per-week, in-center hemodialysis versus 3-days-per week treatment: a randomized crossover pilot trial through the Midwest Pediatric Nephrology Consortium.

Benjamin L Laskin, Guixia Huang, Eileen King, Denis F Geary, Christoph Licht, Joshua P Metlay, Susan L Furth, Tom Kimball, Mark Mitsnefes

Abstract readMulticenter StudyRandomized Controlled Trial
In one paragraph

Trial report in Pediatric nephrology (Berlin, Germany), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors.

Benjamin L LaskinDivision of Nephrology, The Children's Hospital of Philadelphia, 34th Street and Civic Center Boulevard, Philadelphia, PA, 19104, USA. laskinb@email.chop.edu.
Guixia HuangDivision of Biostatistics and Epidemiology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA.
Eileen KingDivision of Biostatistics and Epidemiology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA.
Denis F GearySidra Medical and Research Center, Doha, Qatar.
Christoph LichtDivision of Nephrology, The Hospital for Sick Children, Toronto, Canada.
Joshua P MetlayDivision of General Internal Medicine, Massachusetts General Hospital, Boston, MA, USA.
Susan L FurthDivision of Nephrology, The Children's Hospital of Philadelphia, 34th Street and Civic Center Boulevard, Philadelphia, PA, 19104, USA.
Tom KimballDivision of Cardiology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA.
Mark MitsnefesDivision Nephrology and Hypertension, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA.

Funding

INSTITUTIONAL CLINICAL AND TRANSLATIONAL SCIENCE AWARDUL1RR024134 · NCRR · UNIVERSITY OF PENNSYLVANIA · PI FITZGERALD, GARRET A · 2006 to 2011
$70.4M
Institutional Clinical and Translational Science AwardUL1TR000003 · NCATS · UNIVERSITY OF PENNSYLVANIA · PI FITZGERALD, GARRET A · 2012 to 2015
$38.9M
CTSA INFRASTRUCTURE FOR PEDIATRIC RESEARCHUL1RR026314 · NCRR · UNIVERSITY OF CINCINNATI · PI HEUBI, JAMES E. · 2009 to 2011
$14.3M
Career Development in Comparative Effectiveness ResearchKM1CA156715 · NCI · UNIVERSITY OF PENNSYLVANIA · PI METLAY, JOSHUA P · 2010 to 2010
$2.5M
Cardiovascular Disease in Children with Chronic Kidney DiseaseK24DK090070 · NIDDK · CINCINNATI CHILDRENS HOSP MED CTR · PI MITSNEFES, MARK M. · 2011 to 2015
$839k
Immune dysregulation and kidney disease after hematopoietic cell transplantK23DK101600 · NIDDK · CHILDREN'S HOSP OF PHILADELPHIA · PI LASKIN, BENJAMIN LEWIS · 2015 to 2018
$715k
NCATS NIH HHS UL1 TR000003NCI NIH HHS KM1 CA156715NCRR NIH HHS UL1 RR024134NCRR NIH HHS UL1 RR026314NIDDK NIH HHS K23 DK101600NIDDK NIH HHS K24 DK090070
6 · The paper itself

Abstract

backgroundNo controlled trials in children with end-stage kidney disease have assessed the benefits of more frequently administered hemodialysis (HD).

methodsWe conducted a multicenter, crossover pilot trial to determine if short, more frequent (5 days per week) in-center HD was feasible and associated with improvements in blood pressure compared with three conventional HD treatments per week. Because adult studies have not controlled for the weekly duration of dialysis, we fixed the total treatment time at 12 h a week of dialysis during two 3-month study periods; only frequency varied from 5 to 3 days per week between study periods.

resultsEight children (median age 16.7 years) consented at three children's hospitals. The prespecified primary composite outcome was a sustained 10% decrease in systolic blood pressure and/or a decrease in antihypertensive medications relative to each study period's baseline. Among the six patients completing both study periods, five (83.3%) experienced the primary outcome during HD performed 5 days per week but not 3 days per week; one of the six (16.7%) achieved that outcome during 3-day but not 5-day (p = 0.22) per week HD. During 5-day HD, all patients had significantly more treatments during which their pre-HD systolic (p = 0.01) or diastolic (p = 0.01) blood pressure was 10% lower than baseline.

conclusionsWe observed that more frequent HD sessions per week was feasible and associated with improved blood pressure control, but barriers to changing thrice-weekly standard of care include financial reimbursement and the time demands associated with more frequent treatments.

Indexed as

AdolescentAntihypertensive AgentsBlood Pressure DeterminationCross-Over StudiesFeasibility StudiesFemaleHumansHypertensionInsurance, Health, ReimbursementKidney Failure, ChronicMaleMidwestern United StatesNephrologyPilot ProjectsRenal DialysisTime FactorsAntihypertensive AgentsChildrenEnd-stage kidney diseaseHypertensionMore frequent hemodialysis

Identifiers

PMID28389745
PMCPMC5485844

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.